MMX公司
医学
安慰剂
双盲
胃肠病学
内科学
病理
替代医学
计算机科学
操作系统
作者
Lukas Michaja Balsiger,Javier Santos,Jordi Serra,Hubert Piessevaux,D Baert,M Storr,Guido Basilisco,Alessandro Mazzetti,Luigi Moro,Mara Gerloni,Luigi Longo,Alessandra Gentili,Jan Tack
标识
DOI:10.14309/ajg.0000000000003236
摘要
Treatment with nonresorbable antibiotics is effective in diarrhea-predominant irritable bowel syndrome (IBS-D). Multimatrix (MMX) formulations ensure targeted drug delivery to the mid-distal small bowel and colon-traditionally considered the origin of IBS symptoms. To assess the efficacy of rifamycin SV-MMX for the treatment of IBS-D.
科研通智能强力驱动
Strongly Powered by AbleSci AI